MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Ocular Therapeutix Inc

Suletud

SektorTervishoid

11.92 6.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.17

Max

11.93

Põhinäitajad

By Trading Economics

Sissetulek

-3.8M

-68M

Müük

2.8M

13M

Kasumimarginaal

-503.856

Töötajad

274

EBITDA

146K

-64M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+85.49% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. nov 2025

Turustatistika

By TradingEconomics

Turukapital

544M

2.5B

Eelmine avamishind

5.68

Eelmine sulgemishind

11.92

Uudiste sentiment

By Acuity

68%

32%

342 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Ocular Therapeutix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. okt 2025, 23:25 UTC

Suurimad hinnamuutused turgudel

Salesforce Rises on New FY30 Financial Targets

15. okt 2025, 18:52 UTC

Tulu
Suurimad hinnamuutused turgudel

Prologis Shares Gain on Raised Outlook, Data Center Growth

15. okt 2025, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software to Buy U.K.'s Tecvia Holding

15. okt 2025, 17:19 UTC

Omandamised, ülevõtmised, äriostud

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15. okt 2025, 17:11 UTC

Omandamised, ülevõtmised, äriostud

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15. okt 2025, 23:48 UTC

Market Talk

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15. okt 2025, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. okt 2025, 22:37 UTC

Market Talk

Economic Stars Are Aligning for RBA -- Market Talk

15. okt 2025, 21:44 UTC

Tulu

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15. okt 2025, 20:50 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

15. okt 2025, 20:44 UTC

Omandamised, ülevõtmised, äriostud

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15. okt 2025, 20:44 UTC

Omandamised, ülevõtmised, äriostud

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15. okt 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15. okt 2025, 20:34 UTC

Tulu

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15. okt 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15. okt 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15. okt 2025, 19:06 UTC

Tulu

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15. okt 2025, 19:04 UTC

Market Talk

Oil Futures Post Back-to-Back Losses -- Market Talk

15. okt 2025, 18:46 UTC

Market Talk

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15. okt 2025, 18:23 UTC

Tulu

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15. okt 2025, 17:37 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15. okt 2025, 17:34 UTC

Market Talk

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15. okt 2025, 16:57 UTC

Tulu

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15. okt 2025, 16:51 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica Doesn't Disclose Financial Details

15. okt 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15. okt 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15. okt 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15. okt 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15. okt 2025, 16:47 UTC

Omandamised, ülevõtmised, äriostud

EssilorLuxottica Buys Ikerian

15. okt 2025, 16:34 UTC

Market Talk

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ocular Therapeutix Inc Prognoos

Hinnasiht

By TipRanks

85.49% tõus

12 kuu keskmine prognoos

Keskmine 20.83 USD  85.49%

Kõrge 31 USD

Madal 14 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

13

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.97 / 7.62Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

342 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat